Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

167.82 +0.71 (+0.42%)
Streaming Delayed Price Updated: 11:00 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
News headline image
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value ↗
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
News headline image
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery ↗
Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google's AI R&D division DeepMind, has announced strategic part 
Via Benzinga
Topics Artificial Intelligence
News headline image
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis ↗
Isomorphic Labs will get upfront cash and milestone payments. 
Via Investor's Business Daily
News headline image
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion ↗
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... 
Via Talk Markets
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
News headline image
Big Players' Recent Trades in NVS Options ↗
 
Via Benzinga
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
News headline image
(NVS) - Analyzing Novartis's Short Interest ↗
 
Via Benzinga
News headline image
Voyager Therapeutics Stock Tanked After-Hours - Here's Why ↗
Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public offering  
Via Benzinga
News headline image
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
News headline image
Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today? ↗
Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance pot 
Via Benzinga
News headline image
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign ↗
The company inked an expanded collaboration deal with Novartis to test out gene therapies. 
Via Investor's Business Daily
News headline image
Why Is Neurology Focused Cingulate Stock Trading Higher Today? ↗
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f 
Via Benzinga
News headline image
Why Is Cytokinetics (CYTK) Stock Up 70% Today? ↗
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals ↗
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
News headline image
These 3 Big Pharma Stocks Are Making Big Plays With AI ↗
Opportunity is in the air with AI, and these pharma giants are seizing the moment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
News headline image
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside ↗
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
News headline image
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug ↗
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga
News headline image
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now? ↗
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
News headline image
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients ↗
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a... 
Via Benzinga
News headline image
Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease ↗
Novartis AG (NYSE: NVS) announced  
Via Benzinga
News headline image
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks ↗
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
News headline image
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising ↗
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale. 
Via Investor's Business Daily
News headline image
Novartis' Rare Blood Disorder Therapy Scores FDA Approval ↗
The FDA approved Novartis AG's (NYSE 
Via Benzinga
News headline image
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies ↗
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
News headline image
3 Healthcare Stocks to Pick Up Before the Year-End Rally ↗
Explore the potential of healthcare stocks as the U.S. charges ahead with $4.3 trillion in healthcare spending 
Via InvestorPlace
News headline image
Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off ↗
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology),... 
Via Benzinga
News headline image
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. ↗
The company is working on treatments for breast cancer in a market worth $15 billion, according to the CEO. 
Via Investor's Business Daily
News headline image
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and... 
Via Talk Markets
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.